- ousama
- AI & Analytics
- September 17, 2025
- No Comments
Blog Details
Rahul Pathak and Divyata Manvati coauthored this piece.
Heading into 2026, the pharmaceutical and biotech industries face an operating environment in flux. Each year, we step back to assess how the healthcare landscape is shifting and how pharma is adjusting to compete within it.
While today’s uncertainty may feel unnerving, the direction of travel is clear: a near-term situation characterized by lower prices, deglobalization of the drug supply chain, shifting clinical priorities and reduced funding for early-stage innovation.
At the same time, several forces are working in the industry’s favor, headlined (as usual) by breakthrough science and the (continued) acceleration of AI and data maturity.
The external forces reshaping the pharmaceutical industry in 2026
In 2026 four powerful external forces will bear down on the pharma and biotech industries.
1. Regulatory and geopolitical volatility. The U.S. environment is becoming more protectionist and complex, with increased intervention across pricing, clinical standards and oversight. This creates material strategic risk for pharma across cost structure, evidence generation, launch economics and R&D priorities. Since early 2025, the federal government has used its executive authority to advance a set of policy measures aimed at lowering drug prices in the U.S. and encouraging other countries to pay more for innovation. These measures fall into four broad categories:
- Aggressive trade and tariff regime. New U.S. trade measures, including 15% tariffs on pharmaceutical imports and “U.S.-first” production incentives, are raising the cost of globally manufactured products and accelerating reshoring supply strategies. Analysts estimate these tariffs alone could add $13-$19B in industry costs, with some portion likely passed through to customers.
- Innovation funding cuts. Deep workforce and budget reductions across the Food and Drug Administration (FDA), National Institutes of Health and other federal health agencies are constraining the nation’s scientific capacity and slowing early-stage research. These cuts risk a long-term innovation slowdown as agencies lose staff, suspend activities during shutdowns and face multibillion-dollar funding gaps.
- Shifting regulatory priorities. Federal public health priorities are being redirected toward chronic disease and lifestyle interventions, while support for certain modalities—mRNA, for example—has been reduced via canceled BARDA projects and new vaccine evidence standards. At the same time, regulatory requirements are tightening in some areas and loosening in others, creating uneven expectations for evidence generation.
- Coordinated pricing reform through policy. Most-favored nation (MFN) pricing and new Medicaid international-reference models are exerting downward pressure on U.S. drug prices. Combined with expanded biosimilar interchangeability and development cost reductions, these policies threaten both near-term revenue and long-term global investment decisions.
2. Shifting customer and consumer expectations for healthcare. Healthcare providers and systems are under mounting strain, widening care gaps and lowering the perceived value of pharma engagement. As capacity erodes and expectations rise, HCPs have less time and tolerance for traditional pharma interactions. This is pushing HCPs to skip engagements that don’t either save time or add clinical value.
Patients, meanwhile, increasingly seek seamless experiences, transparency and tangible value that the system often struggles to deliver. With care fragmented and time with clinicians limited, patients are increasingly turning to AI-enabled tools, alternative care providers and direct-to-consumer access models to reduce friction, improve affordability and regain agency in their care journeys.
As capacity erodes and expectations rise, HCPs have less time and tolerance for traditional pharma interactions.
Jon Roffman
Global Head of Biopharma



